文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症最初24小时内口服米多君以减少血管活性药物需求:安慰剂对照可行性临床试验

Oral Midodrine Administration During the First 24 Hours of Sepsis to Reduce the Need of Vasoactive Agents: Placebo-Controlled Feasibility Clinical Trial.
PubMed 文献 · Crit Care Explor · 2021-05-06
一句话结论在脓毒症最初24小时内口服米多君10 mg×3次耐受性良好,未观察到严重不良事件,但血管升压药使用时长、去甲肾上腺素当量及ICU住院时间与安慰剂组无显著差异,支持开展II期临床结局试验。

该先导性、两中心、安慰剂对照、双盲随机临床试验纳入32例成人脓毒症(Sepsis-3)患者,在确诊24小时内、尽管及时使用抗生素和30 cc/kg初始静脉液体复苏平均动脉压仍<70 mm Hg者,随机接受米多君10 mg×3次(n=17)或安慰剂(n=15)。米多君组基线肌酐较高(2.0±0.9 vs 1.4±0.6 mg/dL,p=0.03);静脉血管升压药需求中位时长14.5±8.1小时 vs 18.8±7.1小时(p=0.19),去甲肾上腺素当量729±963 vs 983±1569(p=0.59),ICU住院时间2.29天(IQR 1.65-3.9)vs 2.45天(IQR 1.6-3.2)(p=0.36),两组均未观察到严重不良事件。作者认为应开展以临床结局(血管升压药使用时长、中心静脉导管需求、ICU及住院时间)为终点的II期临床试验。

要点

  • 在脓毒症确诊24小时内、尽管及时抗生素和30 cc/kg初始静脉液体复苏平均动脉压仍<70 mm Hg的成人患者中,口服米多君10 mg×3次未观察到严重不良事件。
  • 米多君组静脉血管升压药需求中位时长14.5±8.1小时 vs 安慰剂组18.8±7.1小时,p=0.19,差异未达统计学显著。
  • 米多君组去甲肾上腺素当量729±963 vs 安慰剂组983±1569,p=0.59;ICU住院时间2.29天(IQR 1.65-3.9)vs 2.45天(IQR 1.6-3.2),p=0.36。
  • 米多君组基线肌酐2.0±0.9 mg/dL高于安慰剂组1.4±0.6 mg/dL,p=0.03,为两组唯一基线差异。
  • 作者认为应开展以临床结局为终点的II期临床试验。

适用人群与场景

  • 成人患者(≥18岁),在符合Sepsis-3定义24小时内纳入。
  • 尽管接受及时抗生素和30 cc/kg初始静脉液体复苏,平均动脉压仍<70 mm Hg。
  • 研究场所为Mayo Clinic Rochester和Cleveland Clinic Abu Dhabi的内科ICU。

诊断标准与关键阈值

  • Sepsis-3定义。
  • 平均动脉压<70 mm Hg(尽管接受及时抗生素和初始静脉液体30 cc/kg)。

处置流程与药物剂量

  • 米多君组:米多君10 mg,共3次(口服)。
  • 安慰剂组:安慰剂,共3次。

研究设计与关键结果

  • 设计:先导性、两中心、安慰剂对照、双盲随机临床试验;共32例随机分为米多君组(n=17)和安慰剂组(n=15)。
  • 基线:除米多君组基线肌酐较高(2.0±0.9 mg/dL vs 1.4±0.6 mg/dL,p=0.03)外,两组基线变量无重大差异。
  • 主要终点:静脉血管升压药需求中位时长米多君组14.5±8.1小时 vs 安慰剂组18.8±7.1小时,p=0.19。
  • 次要终点:去甲肾上腺素当量米多君组729±963 vs 安慰剂组983±1569,p=0.59;ICU住院时间米多君组2.29天(IQR 1.65-3.9)vs 安慰剂组2.45天(IQR 1.6-3.2),p=0.36。
  • 不良事件:两组均未观察到严重不良事件。

证据类型、等级与局限

  • 证据类型:先导性、两中心、安慰剂对照、双盲随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,应开展以临床结局(血管升压药使用时长、中心静脉导管需求、ICU及住院时间)为终点的II期临床试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Our preliminary data and observational studies suggested an increasing "off label" use of oral midodrine as a vasopressor sparing agent in various groups of critically ill patients, including those with sepsis. We designed this clinical trial to evaluate the feasibility of use of midodrine hydrochloride in early sepsis to reduce the duration for IV vasopressors and decrease ICU and hospital length of stay.

DESIGN: Pilot, two-center, placebo-controlled, double blinded randomized clinical trial.

SETTING: Medical ICUs at Mayo Clinic Rochester and Cleveland Clinic Abu Dhabi were the study sites.

PATIENTS AND METHODS: Adult patients (≥ 18 yr old) were included within 24 hours of meeting the Sepsis-3 definition if the mean arterial pressure remained less than 70 mm Hg despite receiving timely antibiotics and initial IV fluid bolus of 30 cc/kg.

INTERVENTION: Three doses of 10 mg midodrine versus placebo were administered.

MEASUREMENTS AND MAIN RESULTS: Total 32 patients were randomized into midodrine (n = 17) and placebo groups (n = 15). There were no major differences in baseline variables between the groups except for higher baseline creatinine in the midodrine group (2.0 ± 0.9 mg/dL) versus placebo group (1.4 ± 0.6 mg /dL), p = 0.03. The median duration of IV vasopressor requirement was 14.5 ± 8.1 hours in midodrine group versus 18.8 ± 7.1 hours in the placebo group, p value equals to 0.19. Patients in the midodrine group needed 729 ± 963 norepinephrine equivalent compared with 983 ± 1,569 norepinephrine equivalent in the placebo group, p value equals to 0.59. ICU length of stay was 2.29 days (interquartile range, 1.65-3.9 d) in the midodrine group, compared with 2.45 days (interquartile range, 1.6-3.2 d) in the placebo group, p value equals to 0.36. No serious adverse events were observed in either group.

CONCLUSIONS: Phase II clinical trial powered for clinical outcomes (duration of vasopressor use, need for central venous catheter, and ICU and hospital length of stay) is justified.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Lal A, Trivedi V, Rizvi MS, et al. Oral Midodrine Administration During the First 24 Hours of Sepsis to Reduce the Need of Vasoactive Agents: Placebo-Controlled Feasibility Clinical Trial. Crit Care Explor. 2021. PMID: 33977276. doi:10.1097/CCE.0000000000000382

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。